PODD|Insulet Corp|Price:148.160|Chg%:-10.19

More Details of Insulet Corp Company

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Insulet Corp Info



Ticker SymbolPODD

Company nameInsulet Corp

IPO dateMay 15, 2007

CEOMcevoy (Ashley)

Number of employees3900

Security typeOrdinary Share

Fiscal year-endMay 15

Address100 Nagog Park

CityACTON

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code01720-3440

Phone19786007000

Websitehttps://www.omnipod.com

Ticker SymbolPODD

IPO dateMay 15, 2007

CEOMcevoy (Ashley)

Company Executives of Insulet Corp



Name

Name/Position

Position

Shareholding

Change

Dr. Jessica Hopfield, Ph.D.

Independent Director

27.70K

--

Mr. Michael R. Minogue

Independent Director

18.26K

+18.67%

Mr. Eric Benjamin

Chief Operating Officer

16.55K

-4.75%

Ms. Lauren Budden

Chief Accounting Officer, Group Vice President, Corporate Controller

6.75K

+22.59%

Ms. Laetitia Cousin

Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance

5.36K

+35.90%

Ms. Elizabeth H. (Bess) Weatherman

Independent Director

5.24K

--

Mr. Timothy C. (Tim) Stonesifer

Independent Director

4.22K

+8.71%

Mr. Prem Singh

Senior Vice President - Global Operations

3.11K

-123.87%

Dr. Luciana Borio, M.D.

Independent Director

2.31K

-33.69%

Mr. Timothy J. (Tim) Scannell

Independent Chairman of the Board

--

Name

Name/Position

Position

Shareholding

Change

Dr. Jessica Hopfield, Ph.D.

Independent Director

27.70K

--

Mr. Michael R. Minogue

Independent Director

18.26K

+18.67%

Mr. Eric Benjamin

Chief Operating Officer

16.55K

-4.75%

Ms. Lauren Budden

Chief Accounting Officer, Group Vice President, Corporate Controller

6.75K

+22.59%

Ms. Laetitia Cousin

Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance

5.36K

+35.90%

Ms. Elizabeth H. (Bess) Weatherman

Independent Director

5.24K

--

Revenue Breakdown

Currency: USDUpdated: Mon, Apr 6

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

FY2017

FY2016

By BusinessUSD

Name

Revenue

Proportion

U.S.Omnipod

1.92B

70.89%

International Omnipod

754.30M

27.85%

Drug Delivery

34.10M

1.26%

By RegionUSD

Name

Revenue

Proportion

United States

1.95B

72.15%

All Other

754.30M

27.85%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

U.S.Omnipod

1.92B

70.89%

International Omnipod

754.30M

27.85%

Drug Delivery

34.10M

1.26%

Shareholding Stats

Updated: Sun, May 10

Shareholders

Shareholder Types

Shareholders

Proportion

Fidelity Management & Research Company LLC

8.18%

Vanguard Capital Management, LLC

6.61%

BlackRock Institutional Trust Company, N.A.

6.39%

Capital Research Global Investors

6.37%

Vanguard Portfolio Management, LLC

4.98%

Other

67.48%

Shareholders

Proportion

Fidelity Management & Research Company LLC

8.18%

Vanguard Capital Management, LLC

6.61%

BlackRock Institutional Trust Company, N.A.

6.39%

Capital Research Global Investors

6.37%

Vanguard Portfolio Management, LLC

4.98%

Other

67.48%

Shareholder Types

Shareholders

Proportion

Investment Advisor

65.74%

Investment Advisor/Hedge Fund

26.60%

Hedge Fund

4.98%

Pension Fund

2.66%

Research Firm

2.51%

Sovereign Wealth Fund

1.60%

Bank and Trust

1.45%

Individual Investor

0.32%

Insurance Company

0.06%

Institutional Shareholding



Updated: Sun, Apr 5

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

1624

73.18M

105.65%

-1.62M

2025Q4

1606

71.89M

102.19%

-3.38M

2025Q3

1546

72.07M

102.39%

-3.66M

2025Q2

1541

72.80M

103.47%

-3.81M

2025Q1

1569

72.82M

103.50%

-3.52M

2024Q4

1508

72.57M

103.34%

-4.94M

2024Q3

1436

73.14M

104.31%

-3.15M

2024Q2

1408

72.17M

103.04%

-3.02M

2024Q1

1350

71.60M

102.26%

-3.12M

2023Q4

1320

72.91M

104.42%

-1.52M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Fidelity Management & Research Company LLC

5.66M

8.04%

-1.25M

-18.11%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

4.43M

6.29%

+254.00

+0.01%

Dec 31, 2025

Capital Research Global Investors

4.41M

6.26%

-140.10K

-3.08%

Dec 31, 2025

State Street Investment Management (US)

3.16M

4.48%

+65.32K

+2.11%

Dec 31, 2025

Baillie Gifford & Co.

2.05M

2.91%

-43.33K

-2.07%

Dec 31, 2025

Geode Capital Management, L.L.C.

2.01M

2.85%

+41.02K

+2.09%

Dec 31, 2025

American Century Investment Management, Inc.

1.58M

2.25%

+177.56K

+12.62%

Dec 31, 2025

ClearBridge Investments, LLC

1.39M

1.97%

-79.75K

-5.44%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Langar Global HealthTech ETF

7.26%

Innovator IBD Breakout Opportunities ETF

4.88%

Global X HealthTech ETF

4.76%

Goldman Sachs Future Health Care Equity ETF

4.2%

First Trust Nasdaq Lux Digi Health Solutions ETF

3.7%

iShares Health Innovation Active ETF

3%

Congress SMid Growth ETF

2.82%

iShares U.S. Medical Devices ETF

2.62%

FT Raymond James Multicap Growth Equity ETF

2.3%

Acruence Active Hedge US Equity ETF

2.27%

Langar Global HealthTech ETF

Proportion7.26%

Innovator IBD Breakout Opportunities ETF

Proportion4.88%

Global X HealthTech ETF

Proportion4.76%

Goldman Sachs Future Health Care Equity ETF

Proportion4.2%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proportion3.7%

iShares Health Innovation Active ETF

Proportion3%

Congress SMid Growth ETF

Proportion2.82%

iShares U.S. Medical Devices ETF

Proportion2.62%

FT Raymond James Multicap Growth Equity ETF

Proportion2.3%

Acruence Active Hedge US Equity ETF

Proportion2.27%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data